KR20190055785A - Ginsenoside composition for treating, improving, or preventing inflammatory disease, and method for preparing the same - Google Patents

Abstract

The present invention relates to a ginsenoside composition for treating, alleviating, or preventing inflammatory diseases containing a ginseng extract, in which 30 to 70 wt% of a total ginsenoside content is contained and 0.01 to 4 wt% of a Rg3 content is contained relative to the total ginsenoside weight. A ginseng extract composition of the present invention has an increased content of ginsenoside by the treatment of ginsenoside glycosidase, consisting of an amino acid sequence of sequence number 1, and has a relatively increased content of minor saponins in ginsenoside, thereby being able to improve antioxidant, anti-inflammatory, and anti-aging functions.

Description

Ginsenoside composition for the treatment, improvement or prevention of inflammatory diseases and its manufacturing method {GINSENOSIDE COMPOSITION FOR TREATING, IMPROVING, OR PREVENTING INFLAMMATORY DISEASE, AND METHOD FOR PREPARING THE SAME}

The present invention relates to a ginsenoside composition and a method for producing the same, and more particularly, to obtain a new composition having a different physiological activity than before by metabolizing the existing ginseng ginsenoside, through which it is also used in the prevention and treatment of inflammatory diseases. It relates to a method of obtaining a composition that works.

The saponin component, which contains the main physiologically active ingredients of ginseng or red ginseng, has a chemical structure different from that of saponins found in other plants, and it is specifically named as ginsenoside in the sense of Ginseng glycoside. . Such ginsenosides are Protopanaxadiol-type, Protopanaxatriol-type, and oleanolic acid-type ginsenosides according to the structure of aglycone. It can be classified into three categories: These three groups are again the position and number of sugar moieties (aglycones) attached by glycoside bonds at the C-3, C-6 and C-20 positions of the ring in the compound structure. Among them, Rg1, Re, Rb1, Rc, and Rb2 are major ginsenosides, which account for more than 90% of the total saponin (Park, 2004), and these are orally administered to the human body due to their large size. In this case, it is known that it is difficult to be absorbed directly. Therefore, these major ginsenosides require a conversion process that removes sugar (deglycosylated) in order to effectively exhibit physiological activity in an in vivo test (Tawab et al., 2003; Akao et al., 1998). On the other hand, in recent decades, excellent pharmacological efficacy of ginsenosides having minor forms such as Rg3, Rh2 and compound K (compound K) has been revealed. As these research results are published, trace amounts of ginsenosides F2, Rg3, Rh1, Rh2 and compounds K (compound K, CK), Gyp17, Rg3, C-Mc1, C-Mx1, F2, etc. There are many studies on minor ginsenosides, and there is a demand for a method capable of increasing the content ratio of a specific ginsenoside having such a minor form.

Chemical decomposition method (De Mayo et al., canad. J. Chem., 43, 2033, 1965), enzymatic method (Kitagawa et al., Terahedron Letters, 30, 2283, as a method for producing minor ginsenosides, which is a trace amount of saponin). 1974), and a method using the synthesis of glycosides (No. 10-2005-0007250), etc., have been proposed, but such methods 1) require several steps in the manufacturing process, or 2) the desired component is lost in the manufacturing process. And, 3) using a catalyst that is not suitable for food, or 4) showing a low yield, there has still been a limit to mass production.

In particular, among the enzymatic methods, the types of enzymes that can be used include ginsenoside glycosidase, α-L-arabinopyranosidase, and α-L-arabinofuranosidase. It has been reported that enzymes such as (α-L-arabinofuranosidase) and α-L-rhamnosidase biotransform major ginsenosides such as Rb1, Rb2, Rc and Re. . That is, the saponins extracted from ginseng are mostly formed of complex saponins such as Rg1, Re, Rb1, Rb2, Rc and Rb3, so the number, type and location of sugars bound by glycosidic bonds are different. There is a situation in which a large amount of various enzymes are required.

Korean Patent Application Publication No. 10-2016-0086498 Korean Registered Patent Publication No. 10-1647631

It is an object of the present invention to bioconvert ginsenoside, a major saponin contained in natural ginseng, to ginsenoside glycosides having a specific amino acid sequence, so that the total ginsenoside content is remarkably high, among the total ginsenosides. It is to provide a ginsenoside composition for the treatment, improvement or prevention of inflammatory diseases comprising a ginseng extract having a high content of minor saponins having a high physiological activity as an active ingredient.

According to an aspect of the present invention,

Ginseng for the treatment, improvement or prevention of inflammatory diseases containing ginseng extract containing 30 to 70% by weight of total ginsenosides and 0.01 to 4% by weight of Rg3 content relative to the total ginsenosides weight as an active ingredient A cenoside composition is provided.

The ginsenoside composition may contain 2 to 30% by weight of any one selected from Gyp17, Rg3, C-Mc1, C-Mx1 and F2 based on the total ginsenoside weight.

The ginsenoside composition is characterized in that the sum of the weights of Gyp17, Rg3, C-Mc1, C-Mx1 and F2 is 30 to 80% by weight based on the total ginsenoside weight.

The ginsenoside composition may be a pharmaceutical composition for treating or preventing inflammatory, or a food composition for improving or preventing inflammatory disease.

The inflammatory diseases include inflammatory skin disease, Crohn's disease, ulcerative colitis, peritonitis, osteomyelitis, cellulitis, meningitis, encephalitis, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, Osteoarthritis, gout, spondyloarthropathy, ankylosing spondylitis, intestinal spondylitis, juvenile arthritis, juvenile ankylosing spondylitis, reactive arthritis, infectious arthritis, systemic lupus erythematosus, recursive fever, psoriasis, post-infectious arthritis, gonococcal arthritis, tuberculosis Arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, rheumatoid polymyalgia, joint cell arteritis, calcium crystallization arthritis, non-articular rheumatism, bursitis, tendonitis, and hemoglobin.

According to another aspect of the present invention,

(a) extracting ginseng with water, a lower alcohol having 1-4 carbon atoms, or a mixed solvent of the lower alcohol and water to prepare a ginseng extract; And (b) enzymatic treatment of the ginseng extract with ginsenoside glycosides consisting of the amino acid sequence of SEQ ID NO: 1; Jin for the treatment, improvement or prevention of inflammatory diseases comprising a ginseng extract as an active ingredient A method of preparing a cenoside composition is provided.

According to the enzyme treatment, at least one selected from ginsenosides Re, Rb1, Rc, Rb2, Rb3 and Rd is all or partially bioconverted to at least one selected from Gyp17, Rg3, C-Mc1, C-Mx1 and F2. Can be.

The ginsenoside composition for the treatment, improvement or prevention of inflammatory diseases comprising the ginseng extract of the present invention as an active ingredient contains ginsenoside, a major saponin contained in natural ginseng, and ginsenoside glycosides having a specific amino acid sequence. By bioconversion to Sidase, the total ginsenoside content is remarkably high, and the physiological activity is increased by increasing the minor saponin content of the total ginsenosides, thereby improving antioxidant, anti-inflammatory, and anti-aging functions.

1 shows ginsenoside size markers.
2 is an HPLC analysis result showing the ginsenoside component before the reaction.
3 is an HPLC analysis result showing ginsenoside components after reaction with ginsenoside glycosides.
4 is a result of a cytotoxicity test for the ginsenoside composition of Example 1.
5 is a test result of TNF-α expression measurement for the ginsenoside composition of Example 1.
6 is an IL-6 expression measurement test result for the ginsenoside composition of Example 1.
7 is a measurement test result of the inhibition of production of nitric oxide (NO) for the ginsenoside composition of Example 1. FIG.
8 is an amino acid sequence of ginsenoside glycosidase used in the present invention.

Since the present invention can apply various transformations and have various embodiments, specific embodiments are illustrated in the drawings and will be described in detail in the detailed description. However, this is not intended to limit the present invention to a specific embodiment, it should be understood to include all conversions, equivalents, and substitutes included in the spirit and scope of the present invention. In describing the present invention, when it is determined that a detailed description of a related known technology may obscure the subject matter of the present invention, a detailed description thereof will be omitted.

Hereinafter, the ginsenoside composition for the treatment, improvement or prevention of inflammatory diseases of the present invention will be described.

The ginsenoside composition of the present invention comprises a ginseng extract containing a total ginsenoside content of 30 to 70% by weight, and an Rg3 content of 0.01 to 4% by weight based on the total ginsenoside weight as an active ingredient. It is done.

The ginsenoside composition preferably contains 2 to 30% by weight of any one selected from Gyp17, Rg3, C-Mc1, C-Mx1 and F2 based on the total ginsenoside weight.

In the ginsenoside composition, it is preferable that the sum of the weights of Gyp17, Rg3, C-Mc1, C-Mx1 and F2 is 30 to 80% by weight based on the total ginsenoside weight.

The ginsenoside composition may be a pharmaceutical composition for treating or preventing inflammatory diseases, or a food composition for improving or preventing inflammatory diseases.

The inflammatory diseases include inflammatory skin disease, Crohn's disease, ulcerative colitis, peritonitis, osteomyelitis, cellulitis, meningitis, encephalitis, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, Osteoarthritis, gout, spondyloarthropathy, ankylosing spondylitis, intestinal spondylitis, juvenile arthritis, juvenile ankylosing spondylitis, reactive arthritis, infectious arthritis, systemic lupus erythematosus, recursive fever, psoriasis, post-infectious arthritis, gonococcal arthritis, tuberculosis Arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, rheumatoid polymyalgia, joint cell arteritis, calcium crystallization arthritis, non-joint rheumatism, bursitis, tendonitis, hemoglobin, etc. Not limited.

Hereinafter, a method of preparing a ginsenoside composition for treating, improving or preventing inflammatory diseases according to the present invention will be described.

First, ginseng is extracted with water, a lower alcohol having 1-4 carbon atoms , or a mixed solvent of the lower alcohol and water to prepare a ginseng extract (step a).

The extraction solvent used in the present invention is preferably water, a lower alcohol having 1-4 carbon atoms, and a mixed solvent of the lower alcohol and water, but the scope of the present invention is not limited thereto, and acetone, ethyl acetate, Chloroform, butyl acetate, 1,3-butylene glycol, hexane, diethyl ether, and the like can also be used.

The term “extract” as used herein has a meaning commonly used as a crude extract in the art, but may include a fraction obtained by additionally fractionating the extract. Further, it may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze drying, or spray drying.

Thereafter, the enzyme-treated ginseng extract in the jinse industrial grade articles lycopene during Days consisting of the amino acid sequence of SEQ ID NO: 1 (step b).

The amino acid sequence of the ginsenoside glycosidase is as shown in FIG. 7.

According to the enzyme treatment, at least one selected from ginsenosides Re, Rb1, Rc, Rb2, Rb3 and Rd is all or partially bioconverted to at least one selected from Gyp17, Rg3, C-Mc1, C-Mx1 and F2. Can be.

Accordingly, the ginsenoside content in the ginseng extract is significantly increased by 3 to 7 times, as well as the generation of minor saponins having high physiological activity among the total ginsenosides, such as Gyp17, Rg3, C-Mc1, C-Mx1 and F2, and thereby antioxidant, Anti-inflammatory and anti-aging functions can be remarkably improved.

Meanwhile, in the present specification, the term “including as an active ingredient” means including an amount sufficient to achieve the efficacy or activity of the ginsenoside composition. In one embodiment of the present invention, the ginsenoside composition in the composition of the present invention is, for example, 0.001 mg/kg or more, preferably 0.1 mg/kg or more, more preferably 1 mg/kg or more, even more. Preferably it contains 10 mg/kg or more. Since the ginsenoside composition is a natural product and does not have side effects on the human body even if it is administered in an excessive amount, the upper limit of the quantity of the ginsenoside composition included in the composition of the present invention can be selected and implemented within an appropriate range by a person skilled in the art.

In addition to the active ingredients, the pharmaceutical composition of the present invention may be prepared using a physiologically acceptable auxiliary agent, and the auxiliary agent includes an excipient, a disintegrant, a sweetener, a binder, a coating agent, an expanding agent, a lubricant, and a lubricant. Alternatively, flavoring agents and the like can be used.

For administration, the pharmaceutical composition may contain one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients, and may be preferably formulated into a pharmaceutical composition.

The formulation form of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, trackcacanth or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, sterilization and biocompatible solutions, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and these One or more of the components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injection formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration.

A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, mode of administration, age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the patient, and is usually As such, a skilled physician can easily determine and prescribe an effective dosage for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.0001-10 g/kg.

The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person skilled in the art, or It can be manufactured by being enclosed in a multi-volume container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or a stabilizer.

The food composition according to the present invention can be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen noodles, other noodles, gums, ice creams, vitamin complexes, health supplements. There are foods.

The food composition of the present invention may include a ginsenoside composition as an active ingredient, as well as an ingredient commonly added during food production, and, for example, include proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. do. Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made of drinks and beverages, in addition to the ginsenoside composition, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be further included.

* The present invention provides a health functional food comprising a ginsenoside composition as an active ingredient. Health functional foods are foods prepared by adding a ginsenoside composition to food materials such as beverages, teas, spices, chewing gums, confectionery, or encapsulating, powdering, and suspending, and when ingested, they have a specific effect on health. It means coming, but unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time by using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. The amount of ginsenoside composition added in such health functional foods cannot be uniformly regulated depending on the type of health functional food to be targeted, but can be added within the range that does not damage the original taste of the food. It is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight. In addition, in the case of health functional foods in the form of pills, granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.

[Example]

Example One: Ginsenoside Biotransformation

For ginseng, red rice ginseng was purchased (Daedong Korea Ginseng, Korea) and saponin was extracted using ethanol. The extracted saponin was dissolved using tertiary purified water, and the reaction was ginsenoside glycosidase consisting of the amino acid sequence of SEQ ID NO: 1 in a 50 mM phosphate buffer (pH 7.0) solution: substrate = 1: 4,000 (molar ratio , Molar Ratio) was added at a ratio and carried out for one day in a shaking incubator at 37°C. After completion of the reaction, it was concentrated to 30-50% of the initial reaction volume using a rotary evaporator (R300, BUCHI). The concentrate was mixed with the same amount of n-butanol again, and then centrifuged using a centrifuge. Only the supernatant was separated and the solvent was evaporated by centrifugation in a low-temperature vacuum state (Speed Vac. Drying). The dried reactants were powdered using a mixer, and after powdering, they were separately dried in a dryer at 60° C. for 48 hours.

[Test Example]

Test example 1: Confirmation of biotransformation

Separately dried reactants according to Example 1 were analyzed for the composition using High Performance Liquid Chromatography (HPLC). 1 shows ginsenoside size markers. In addition, the ginsenoside components before the reaction with ginsenoside glycosides are shown in Tables 1 and 2 below, and the ginsenoside components after the reaction with ginsenoside glycosides are shown in Table 2 below. It is shown in 3.

Composition of ginseng extract before ginsenoside glycosides reaction Title Retention Time (min.) Area Ratio (%) Content (%) Ingredient ratio (%) Area Ratio (%) Components CH 1 1.2333 43.67 52.36 77.41 Carbohydrates (CH) CH 2 1.7000 4.88 5.85 CH 3 1.8500 16.01 19.20 Re 4.4000 0.67 0.80 11.65 6.89 Ginsenosides Rb1 4.8800 3.56 4.27 36.63 Rc 5.1667 2.48 2.97 25.51 Rb2/3 5.4333 2.09 2.51 21.50 Rd 6.0333 0.92 1.10 9.47 Gyp17 0.00 0.00 C- Mc1 0.00 0.00 C- Mx1 0.00 0.00 F2 0.00 0.00 Rg3 0.00 0.00 Unknown1 12.9833 0.58 0.70 10.94 Lipid Unknown2 13.9167 1.74 2.09 Unknown3 15.6167 6.80 8.15 Sum 83.40 100.00 100.00

Composition of ginseng extract after ginsenoside glycosides reaction Title Retention Time (min.) Area Ratio (%) Content (%) Ingredient ratio (%) Area Ratio (%) Components CH 1 1.2833 6.78 9.23 34.61 Carbohydrates (CH) CH 2 1.6833 9.91 13.49 CH 3 1.8500 8.73 11.89 Re 4.3667 1.09 1.48 47.96 3.09 Ginsenosides Rb1 4.8667 3.56 4.85 10.11 Rc 5.2333 3.63 4.94 10.31 Rb2/3 5.5500 4.17 5.68 11.84 Rd 6.1833 2.59 3.53 7.35 Gyp17 6.6167 6.76 9.20 19.19 C- Mc1 7.0167 2.99 4.07 8.49 C- Mx1 7.2667 4.12 5.61 11.70 F2 8.2167 5.53 7.53 15.70 Rg3 9.9333 0.78 1.06 2.21 Unknown1 12.8333 1.78 2.42 17.43 Lipid Unknown2 13.7833 2.31 3.15 Unknown3 15.5167 8.71 11.86 Sum 73.44 100.00 100.00

According to this, the ginsenoside content in the ginseng extract increased more than four times from 11.65% to 47.96%, and looking at the composition of ginsenosides, minor saponins Gyp17, Rg3, C-Mc1, C-Mx1 and It can be seen that the composition of ginsenosides changed significantly due to biotransformation to F2.

Test example 2: Ginsenoside Efficacy test

Using the saponin sample prepared according to Example 2, in vitro (in vitro ) experiments were carried out.

(1) Cytotoxicity test

Macrophage RAW264.7 treated with 1 μg/ml of LPS (lipopolysaccharide) and untreated were dispensed into a 96-well plate at 1×10 ⁴ cells/well, and cultured for 8 hours. After incubation, a new culture solution (Eagle's minimal essential medium (DMEM) medium containing 10% FBS (fetal bovine serum) and 1% penicillin) was replaced, and the ginsenoside composition of Example 1 was 1.3 and 2.5, respectively. , 5, 10 ㎍ / ㎖ and incubated for 24 hours. After incubation, 10 µl of WST solution was added to each well, and then reacted for 30 minutes in a cell incubator, and the change in absorbance at 450 nm was measured to indicate the cell viability relative to the control as a percentage, and the results are shown in FIG. 4. . According to this, it was confirmed that there was no cytotoxicity because the cell viability was increased by the treatment of the ginsenoside complex of Example 1.

(2) TNF-α expression measurement

In the same manner as in the above method, RAW264.7 cells treated with or without LPS were cultured, and the culture medium and cells were placed in a 1 ml tube and centrifuged. Then, a supernatant was obtained and TNF-α was The amount was measured and the results are shown in FIG. 5. According to this, it was found that the production of TNF-α decreased as the throughput of the ginsenoside complex increased.

(3) IL-6 expression measurement

IL-6 expression was measured by the same method as TNF-α expression measurement, and the results are shown in FIG. 6. According to this, it was found that the production of IL-6 was significantly reduced from 1.3 µg/ml of the ginsenoside complex.

(4) Measurement of inhibition of formation of nitric oxide (NO)

The culture solution obtained in the same manner as the above method was measured for nitric oxide production using a NO detection kit (Intron Biotechnology, Korea), and the results are shown in FIG. 7. According to this, it was confirmed that the amount of nitric oxide produced was reduced depending on the treatment amount of the ginsenoside composition of Example 1, so that the anti-inflammatory effect was excellent.

In the above, the embodiments of the present invention have been described, but those of ordinary skill in the art will add, change, delete or add components within the scope not departing from the spirit of the present invention described in the claims. Various modifications and changes can be made to the present invention by means of the like, and it will be said that this is also included within the scope of the present invention.

<110> BEESEN Bio. Co., Ltd. <120> GINSENOSIDE COMPOSITION FOR TREATING, IMPROVING, OR PREVENTING INFLAMMATORY DISEASE, AND METHOD FOR PREPARING THE SAME <130> HPC-7597 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 421 <212> PRT <213> Artificial Sequence <220> <223> 6MT BGL167 <400> 1 Thr Pro Met Thr Asn Pro Phe Pro Gln Asp Phe Leu Trp Gly Val Ala 1 5 10 15 Thr Ala Gly His Gln Val Glu Gly Asn Asn Val Asn Ser Asp Val Trp 20 25 30 Phe Leu Glu His Leu Pro Gly Thr Ile Phe Ala Glu Pro Ser Gly Asp 35 40 45 Ala Val Asp His Tyr His Arg Tyr Arg Glu Asp Ile Ala Leu Ile Ala 50 55 60 Gly Leu Gly Phe Thr Ser Tyr Arg Phe Ser Val Glu Trp Ala Arg Ile 65 70 75 80 Glu Pro Glu Glu Gly His Phe Ser Val Ala Ala Leu Asp His Tyr Lys 85 90 95 Arg Val Leu Glu Ala Cys Arg Glu His Gly Leu Thr Pro Val Val Thr 100 105 110 Phe His His Phe Ala Ser Pro Leu Trp Leu Leu Arg Ser Gly Gly Trp 115 120 125 Glu Gly Glu Arg Thr Pro Glu Leu Phe Ala Arg Tyr Cys Gly Arg Val 130 135 140 Met Ala His Leu Gly Asp Leu Ile Gly Val Ala Cys Thr Leu Asn Glu 145 150 155 160 Pro Asn Leu Pro Trp Leu Leu Glu Ser Phe Gly Ala Gly Gly Glu Ala 165 170 175 Pro Glu Asn Arg Gly Lys Val Pro Met Trp Ala Ala Ala Ala Gln Arg 180 185 190 Leu Gly Val Asp Ala Ser Thr Val Ala Pro Phe Trp Phe Cys Ser Thr 195 200 205 Glu Ala Gly Phe Asn Val Lys Leu Ala Ala His Lys Ala Ala Thr Glu 210 215 220 Ala Ile Lys Ala Trp Arg Pro Asp Leu Arg Val Gly Trp Thr Leu Ala 225 230 235 240 Asn Ser Asp Ile Gln Ser Val Pro Gly Gly Glu Glu Ile Ala Ala Gln 245 250 255 Val Arg Arg Asp Val Asn Glu Arg Phe Leu Glu Ala Ser Arg Gly Asp 260 265 270 Asp Phe Val Gly Ile Gln Thr Tyr Gly Arg Thr Val Tyr Gly Pro Asp 275 280 285 Gly His Ala Pro Ala Pro Glu Gly Val Ala Val Asn Gln Met Gly Trp 290 295 300 Glu Ile Tyr Pro Gln Ala Leu Glu Ala Thr Ile Arg Glu Ala Trp Arg 305 310 315 320 Val Ala Gly Ile Pro Val Met Val Thr Glu Asn Gly Leu Ala Thr Glu 325 330 335 Asp Asp Thr Gln Arg Val Ala Tyr Leu Arg Thr Ala Val Asp Gly Val 340 345 350 Ala Ser Cys Leu Ala Asp Gly Ile Asp Val Arg Gly Tyr Ile Ala Trp 355 360 365 Thr Ala Phe Asp Asn Phe Glu Trp Ala Ala Gly Tyr Gly Pro Lys Phe 370 375 380 Gly Leu Ile Ala Val Asp Arg Ser Thr Gln Glu Arg Thr Pro Lys Glu 385 390 395 400 Ser Ala Arg Trp Leu Gly Asn Phe Ala Arg Gln Gln Ala Pro Ala Glu 405 410 415 Ala Pro Gln Pro Ala 420

Claims (6)

The ginseng extract is an enzyme-treated ginsenoside glycosidase consisting of the amino acid sequence of SEQ ID NO: 1,
The ginseng extract comprises ginsenosides Gyp17, Rg3, C-Mc1, C-Mx1 and F2,
Wherein the ginseng extract has a total ginsenoside content of 30 to 70 wt% and a content of each of Gyp17, Rg3, C-Mc1, C-Mx1 and F2 is 2 to 30 wt% based on the total ginsenoside weight As an active ingredient, a ginsenoside composition for the treatment, improvement or prevention of an inflammatory disease. The method according to claim 1,
The ginsenoside composition according to claim 1, wherein the sum of the weights of Gyp17, Rg3, C-Mc1, C-Mx1 and F2 is 30 to 80% by weight based on the total ginsenoside weight. A ginsenoside composition for the treatment, improvement or prevention of diseases. The method according to claim 1,
Wherein the ginsenoside composition is a pharmaceutical composition for the treatment or prevention of an inflammatory disease, comprising a ginsenoside extract as an active ingredient. The method according to claim 1,
Wherein the ginsenoside composition is a food composition for improving or preventing an inflammatory disease, comprising a ginsenoside extract as an active ingredient. The method according to claim 1,
Wherein said inflammatory disease is selected from the group consisting of inflammatory skin diseases, Crohn's disease, ulcerative colitis, peritonitis, osteomyelitis, meningitis, meningitis, encephalitis, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, cystic fibrosis, stroke, acute bronchitis, Osteoarthritis, gouty arthritis, systemic lupus erythematosus, recurrent fever, psoriasis, post-infectious arthritis, gonococcal arthritis, tuberculosis, osteoarthritis, osteoarthritis, gout, spondyloarthropathies, ankylosing spondylitis, Wherein the composition is any one selected from the group consisting of arthritis, viral arthritis, fungal arthritis, rheumatoid arthritis, rheumatoid multiple myalgia, arthropathic arthritis, calcium crystalloid arthropathy, non-articular rheumatism, bursitis, For the Treatment, Improvement or Prevention of Inflammatory Diseases Containing Extracts as Active Ingredients Side composition. (a) preparing ginseng extract by extracting ginseng with water, a lower alcohol having 1-4 carbon atoms, or a mixed solvent of the lower alcohol and water; And
(b) enzymatically treating the ginseng extract with ginsenoside glycosidase comprising the amino acid sequence of SEQ ID NO: 1,
Wherein at least one selected from ginsenosides Re, Rb1, Rc, Rb2, Rb3 and Rd is partially biotransformed into Gyp17, Rg3, C-Mc1, C-Mx1 and F2 according to the enzyme treatment. Or a pharmaceutically acceptable salt thereof, as an active ingredient, for the treatment, amelioration or prevention of an inflammatory disease.

Images